ArticleNeuropediatrics2026
Patient and Family Perspectives on Clinical Outcomes in Therapy Trials in Megalencephalic Leukoencephalopathy with Subcortical Cysts: An Open Inventory.
Article in Neuropediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine which clinical outcomes are most meaningful to patients with megalencephalic leukoencephalopathy with subcortical cysts (MLC) and their caregivers to enhance clinical trial readiness. Methods: An online survey was developed by the MLC Clinical Expert Consortium and Alliance MLC. The survey, available in eight languages, was distributed via treating neurologists and Alliance MLC, and completed anonymously by patients and caregivers. It included open-ended questions on burdensome daily-life aspects, treatment priorities, and therapy expectations; responses were categorized into functional domains. The survey also included a ranking of key symptom domains. Responses were analyzed separately for caregiver- and patient-reported burden. Subgroup analyses were performed for age (<15 years vs. ≥15 years) and country of residence (Türkiye, India, and Italy). Results: Eighty-five surveys representing 83 patients were included. Motor dysfunction was most frequently reported as most burdensome for both caregivers (74%) and patients (58%), followed by communication and activities of daily living (ADL). Within the motor domain, ambulation was most frequently mentioned. Regarding the ranking, motor function scored highest in 69% of respondents. In patients ≥ 15 years, ambulation was less frequently mentioned, whereas ADL dependency was more frequently reported than in patients <15 years. Comparisons between countries revealed few differences. Hopes for therapy were mainly concerned with motor improvement and halting disease progression. Conclusion: Motor function, particularly ambulation, is the most burdensome and prioritized domain for patients with MLC and their caregivers, regardless of age or country. Incorporating patient-centered priorities into future clinical trial design is essential to ensure that emerging therapies target meaningful improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.